For instance, in a phase I/IIa clinical trial, umbilical cord blood-derived CD19-targeting CAR-NK cells were used to treat patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.